in vitro News and Research

RSS

Naturally selected mutations of SARS-CoV-2 easily duplicated in vitro

In a recent and timely paper, currently available on the bioRxiv preprint server, researchers from Israel and France demonstrated how in vitro evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain (RBD) follows contagious mutation spread – but can also generate an efficient infection inhibitor.

10 Jan 2021

Nuclear DICER complex disrupts cytoplasmic microRNAome in glioblastoma cancer cells

Like Peter Pan, some cells never grow up. In cancer, undifferentiated stem cells may help tumors such as glioblastoma become more aggressive than other forms of the disease.

8 Jan 2021

Researchers develop a low-cost, saliva-optimized RT-LAMP assay for faster detection of SARS-CoV-2

SARS-CoV-2 pandemic has highlighted the shortcomings in emergency response globally and has driven a massive demand for in vitro diagnostic testing technologies. In order to address these issues, researchers from the US recently used the new pH dye LAMPShade Violet (LSV) in RT-LAMP. LSV has better visual contrast between high and low pH and a stronger inflection point, both of which enable easy interpretation of results and reduces ambiguity.

8 Jan 2021

Scientists decipher the structure of protein found in parasites that cause neglected tropical diseases

Brazilian researchers have managed to decipher the structure of a protein found in parasites that cause neglected tropical diseases, paving the way to the development of novel medications.

8 Jan 2021

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Now, an intriguing recent study appeared on the bioRxiv * preprint server describes the use of in vitro evolution to elicit affinity maturation of the viral receptor-binding domain (RBD) of the spike protein to bind the host cell angiotensin-converting enzyme 2 (ACE2) with greater affinity.

7 Jan 2021

Chemicals in e-cigarettes disrupt the gut barrier and trigger inflammation

Touted by makers as a "healthy" alternative to traditional nicotine cigarettes, new research indicates the chemicals found in e-cigarettes disrupt the gut barrier and trigger inflammation in the body, potentially leading to a variety of health concerns.

7 Jan 2021

Potential role of chitinase 3-like-1 in severity of COVID-19

Now, an intriguing preprint research paper on the bioRxiv server reports the identification of an enzyme called chitinase 3-like-1 (CHI3L1) that mediates this age-dependent impact of the virus and could serve as a powerful therapeutic approach in mitigating the severity of COVID-19 in this high-risk group.

7 Jan 2021

Engineered nanodroplets and ultrasound 'drill' can help eliminate tough blood clots

Engineering researchers have developed a new technique for eliminating particularly tough blood clots, using engineered nanodroplets and an ultrasound "drill" to break up the clots from the inside out.

7 Jan 2021

CytoDel successfully delivers neuronal antibody in animal models of botulism

CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the Company's lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine. The complete text of the article titled, "Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism," can be found here.

7 Jan 2021

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Researchers recently demonstrated that chemical agents capable of reducing disulfide (S-S) bonds can be potentially used as antiviral drugs against SARS-CoV-2, the causative pathogen of COVID-19.

6 Jan 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

Glycyrrhizin in licorice root neutralizes SARS-CoV-2 in vitro by inhibiting the main protease Mpro

In a recent bioRxiv* preprint paper, researchers from Germany analyzed aqueous licorice root extract for its neutralizing activity against SARS-CoV-2 in vitro. They identified glycyrrhizin, the primary active ingredient in the root, and revealed the underlying mechanism of viral neutralization.

5 Jan 2021

Researchers develop α-emitting cancer therapy using a novel drug targeting LAT1

A cancer-specific L-type amino acid transporter 1 (LAT1) is highly expressed in cancer tissues.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Could engineered red blood cells be an effective antiviral against SARS-CoV-2?

In a new study, released on the bioRxiv* preprint server, a team of researchers explores the antiviral potential of red blood cells against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19.

24 Dec 2020

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

As the world struggles to contain the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), responsible for over 1.6 million deaths and 76 million infections globally, researchers are trying to pin down the determinants of lethality, of infectivity and of protection. Such data would help contain its spread and develop preventive and therapeutic antivirals and vaccines. A new preprint that appeared recently on the bioRxiv* server describes the high degree of protection afforded by antibodies that target the N-terminal domain (NTD) of the virus.

24 Dec 2020

Kobe University and Sysmex conduct joint research on ELISPOT method for identifying COVID-19

Kobe University and Sysmex Corporation have been engaged in joint research on the ELISPOT method, a new blood test for identifying the novel coronavirus disease (COVID-19).

24 Dec 2020

A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro

Researchers found that cetylpyridinium chloride, found in most mouthwashes, lowers infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, likely by inhibiting viral fusion with target cells. With more tests to prove validity, mouthwashes could be a simple, cheap way of curbing transmission.

24 Dec 2020

Researchers use fruit fly model to understand COVID-19-related neurological complications

Researchers claim to have reproduced disease mechanisms due to coronavirus disease 2019 (COVID-19) in the fruit fly, Drosophila, while also providing proof of the efficacy of one drug against these disease processes. If validated, these findings represent a new understanding of how the virus causes neurological symptoms that could help develop more effective therapies.

23 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

in vitro News and Research

Naturally selected mutations of SARS-CoV-2 easily duplicated in vitro

Nuclear DICER complex disrupts cytoplasmic microRNAome in glioblastoma cancer cells

Researchers develop a low-cost, saliva-optimized RT-LAMP assay for faster detection of SARS-CoV-2

Scientists decipher the structure of protein found in parasites that cause neglected tropical diseases

High-affinity SARS-CoV-2 RBD drives mutation spread, forms basis of new COVID-19 inhibitor

Chemicals in e-cigarettes disrupt the gut barrier and trigger inflammation

Potential role of chitinase 3-like-1 in severity of COVID-19

Engineered nanodroplets and ultrasound 'drill' can help eliminate tough blood clots

CytoDel successfully delivers neuronal antibody in animal models of botulism

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Are SARS-CoV-2 antibodies associated with disease enhancement?

Glycyrrhizin in licorice root neutralizes SARS-CoV-2 in vitro by inhibiting the main protease Mpro

Researchers develop α-emitting cancer therapy using a novel drug targeting LAT1

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Could engineered red blood cells be an effective antiviral against SARS-CoV-2?

Anti-SARS-CoV-2 NTD-directed antibodies are protective against lethal infection

Kobe University and Sysmex conduct joint research on ELISPOT method for identifying COVID-19

A common compound in mouthwashes found to inhibit SARS-CoV-2 in vitro

Researchers use fruit fly model to understand COVID-19-related neurological complications

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News